Use of Buprenorphine in treatment of refractory depression—A review of current literature

Highlights • For treatment resistant depression, augmentation strategies may improve outcome in some, leaving many with disabling and distressing residual symptoms. • Based on the endogenous opioid system literature, Buprenorphine displays a rapid acting antidepressant effect at low doses. • Bupreno...

Full description

Saved in:
Bibliographic Details
Published inAsian journal of psychiatry Vol. 26; pp. 94 - 98
Main Authors Stanciu, Cornel N, Glass, Oliver M, Penders, Thomas M
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.04.2017
Subjects
Analgesics, Opioid - therapeutic use
Antidepressive Agents - therapeutic use
Buprenorphine
Buprenorphine - therapeutic use
Depressive Disorder, Treatment-Resistant - drug therapy
Humans
Internal Medicine
Psychiatry
Treatment Outcome
Treatment resistant depression
Buprenorphine
Treatment resistant depression
Online AccessGet full text

Cover

Abstract Highlights • For treatment resistant depression, augmentation strategies may improve outcome in some, leaving many with disabling and distressing residual symptoms. • Based on the endogenous opioid system literature, Buprenorphine displays a rapid acting antidepressant effect at low doses. • Buprenorphine is well tolerated and although further studies are needed, the limited evidence shows it could be of benefit to patients with treatment resistant depression or those intolerant to conventional standard of care.
AbstractList OBJECTIVECurrent treatment strategies for depressive disorders have limited efficacy, leaving many patients unimproved or with significant residual symptoms. The development of additional treatments represent a significant unmet need for providers. Several lines of evidence suggest that the opioid system may be involved in regulation of mood and incentives salience. Intervention based on modifying central opioid receptors may represent a novel approach to treatment of depressive disorders among those unresponsive to accepted treatments.DATA SOURCESWe searched the English language literature using keywords: Buprenorphine AND Major Depression; Buprenorphine AND Bipolar Depression; Buprenorphine AND Affective Disorders.RESULTSUse of low dose buprenorphine as augmentation of pharmacotherapy for depression has shown promise in several reported studies. Effect size of available randomized controlled studies is comparable if not greater than most accepted augmentation strategies.CONCLUSIONReview of available literature on the use of buprenorphine in individuals with treatment resistant depression demonstrated efficacy in the treatment of depressive disorders. Further prospective randomized controlled trials should be undertaken to evaluate the efficacy of buprenorphine as an adjunct for depression refractory to current pharmacotherapies.
Highlights • For treatment resistant depression, augmentation strategies may improve outcome in some, leaving many with disabling and distressing residual symptoms. • Based on the endogenous opioid system literature, Buprenorphine displays a rapid acting antidepressant effect at low doses. • Buprenorphine is well tolerated and although further studies are needed, the limited evidence shows it could be of benefit to patients with treatment resistant depression or those intolerant to conventional standard of care.
•For treatment resistant depression, augmentation strategies may improve outcome in some, leaving many with disabling and distressing residual symptoms.•Based on the endogenous opioid system literature, Buprenorphine displays a rapid acting antidepressant effect at low doses.•Buprenorphine is well tolerated and although further studies are needed, the limited evidence shows it could be of benefit to patients with treatment resistant depression or those intolerant to conventional standard of care. Current treatment strategies for depressive disorders have limited efficacy, leaving many patients unimproved or with significant residual symptoms. The development of additional treatments represent a significant unmet need for providers. Several lines of evidence suggest that the opioid system may be involved in regulation of mood and incentives salience. Intervention based on modifying central opioid receptors may represent a novel approach to treatment of depressive disorders among those unresponsive to accepted treatments. We searched the English language literature using keywords: Buprenorphine AND Major Depression; Buprenorphine AND Bipolar Depression; Buprenorphine AND Affective Disorders. Use of low dose buprenorphine as augmentation of pharmacotherapy for depression has shown promise in several reported studies. Effect size of available randomized controlled studies is comparable if not greater than most accepted augmentation strategies. Review of available literature on the use of buprenorphine in individuals with treatment resistant depression demonstrated efficacy in the treatment of depressive disorders. Further prospective randomized controlled trials should be undertaken to evaluate the efficacy of buprenorphine as an adjunct for depression refractory to current pharmacotherapies.
Current treatment strategies for depressive disorders have limited efficacy, leaving many patients unimproved or with significant residual symptoms. The development of additional treatments represent a significant unmet need for providers. Several lines of evidence suggest that the opioid system may be involved in regulation of mood and incentives salience. Intervention based on modifying central opioid receptors may represent a novel approach to treatment of depressive disorders among those unresponsive to accepted treatments. We searched the English language literature using keywords: Buprenorphine AND Major Depression; Buprenorphine AND Bipolar Depression; Buprenorphine AND Affective Disorders. Use of low dose buprenorphine as augmentation of pharmacotherapy for depression has shown promise in several reported studies. Effect size of available randomized controlled studies is comparable if not greater than most accepted augmentation strategies. Review of available literature on the use of buprenorphine in individuals with treatment resistant depression demonstrated efficacy in the treatment of depressive disorders. Further prospective randomized controlled trials should be undertaken to evaluate the efficacy of buprenorphine as an adjunct for depression refractory to current pharmacotherapies.
Author Glass, Oliver M
Penders, Thomas M
Stanciu, Cornel N
Author_xml – sequence: 1
  fullname: Stanciu, Cornel N
– sequence: 2
  fullname: Glass, Oliver M
– sequence: 3
  fullname: Penders, Thomas M
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28483102$$D View this record in MEDLINE/PubMed
BookMark eNp9kc1q3DAQx0VJaD7aB-il-NjLbjWSLWspFJLQLwj0kOTUg9DKYyrXK7kjuWVvfYg-YZ-kMpvmkENhQIL5_QfmN2fsKMSAjL0AvgYO6vWwtsO0FhzaNYdSzRN2CrpVK8GFOnr4gz5hZykNnCst6_YpOxG61hK4OGVf7hJWsa8u54kwRJq--oCVD1UmtHmHIS9dwp6sy5H2VYcFTMnH8OfX74vS-eHx58K4mWjBR5-RbJ4Jn7Hj3o4Jn9-_5-zu_bvbq4-r688fPl1dXK9czXVeCaUV76XrtqpvOqk6wK1DaNqNbvgWnGyFFrVFsUFtndZOOgBUNcqm0wpAnrNXh7kTxe8zpmx2PjkcRxswzsmA3ii9qXktCwoH1FFMqaxlJvI7S3sD3CxOzWCKU7M4NRxKNSXz8n78vN1h95D4J7EAbw4AliWLDjLJeQwOO0_osumi_-_4t4_SbvTBOzt-wz2mIc4Uij0DJgnDzc1y1OWmoCQXrdTyL4Own1g
CitedBy_id crossref_primary_10_1038_s41386_021_01192_2
crossref_primary_10_1016_j_genhosppsych_2023_11_003
crossref_primary_10_1093_ijnp_pyx079
crossref_primary_10_1097_01_NME_0000884108_16078_31
crossref_primary_10_1002_jcph_1280
crossref_primary_10_1016_j_ajp_2019_09_033
crossref_primary_10_1038_s41380_019_0503_4
crossref_primary_10_1097_PRA_0000000000000342
crossref_primary_10_1007_s00210_017_1446_4
crossref_primary_10_1016_j_drugalcdep_2020_108122
crossref_primary_10_1007_s40501_018_0152_2
crossref_primary_10_1016_j_bbr_2023_114466
crossref_primary_10_1080_14728214_2024_2345645
crossref_primary_10_1017_S1092852917000876
crossref_primary_10_1038_s41583_018_0092_2
crossref_primary_10_1007_s40265_018_0953_z
crossref_primary_10_1111_acer_15155
crossref_primary_10_3758_s13415_019_00710_6
crossref_primary_10_1007_s11469_017_9856_6
crossref_primary_10_1097_YCO_0000000000000510
Cites_doi 10.1016/j.pharmthera.2009.05.008
10.1038/npp.2014.330
10.1001/archpsyc.62.6.593
10.1016/0165-1781(90)90082-G
10.2174/138161209788168100
10.1007/BF00426537
10.1176/appi.ajp.2015.15070921
10.4088/JCP.13m08725
10.1016/0006-3223(96)00158-8
10.1111/j.1600-0773.1995.tb01041.x
10.1186/1741-7015-9-90
10.1016/0006-8993(90)91301-V
10.1517/14656560903037168
10.1371/journal.pmed.1001547
10.1176/ps.2009.60.11.1439
10.1097/JCP.0b013e31818638a4
10.1038/clpt.2010.352
10.1111/cns.12099
10.1111/j.1749-6632.1982.tb39483.x
10.1080/10550880802122646
10.1177/0269881106060835
10.1097/00004714-199502000-00008
10.1038/clpt.1994.71
10.1111/add.12315
10.1097/00004850-198807000-00007
10.1176/appi.ajp.2015.15040535
10.1016/0006-8993(95)00333-L
10.1176/ajp.153.8.985
10.1016/0740-5472(90)90035-O
10.1111/nyas.12223
10.1016/j.sjpain.2013.05.004
10.1093/bja/ael051
10.1001/archpsyc.63.11.1199
10.1097/ADM.0000000000000045
10.1016/0006-3223(90)90619-D
10.1016/0028-3908(87)90112-2
10.4088/JCP.v63n0913
ContentType Journal Article
Copyright Elsevier B.V.
2017 Elsevier B.V.
Copyright © 2017 Elsevier B.V. All rights reserved.
Copyright_xml – notice: Elsevier B.V.
– notice: 2017 Elsevier B.V.
– notice: Copyright © 2017 Elsevier B.V. All rights reserved.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1016/j.ajp.2017.01.015
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic


MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1876-2026
EndPage 98
ExternalDocumentID 10_1016_j_ajp_2017_01_015
28483102
S1876201816302738
1_s2_0_S1876201816302738
Genre Journal Article
Review
GroupedDBID ---
--K
--M
.1-
.FO
.~1
0R~
1B1
1P~
1~.
23N
4.4
457
4G.
53G
5GY
5VS
6J9
7-5
71M
8P~
AACTN
AADFP
AAEDT
AAEDW
AAGJA
AAGUQ
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAXKI
AAXLA
AAXUO
ABBQC
ABCQJ
ABFRF
ABIVO
ABJNI
ABMAC
ABMZM
ABOYX
ABXDB
ACDAQ
ACGFO
ACGFS
ACRLP
ACXNI
ADBBV
ADEZE
ADMUD
AEBSH
AEFWE
AEKER
AEVXI
AFCTW
AFJKZ
AFKWA
AFRHN
AFTJW
AFXIZ
AGHFR
AGUBO
AGWIK
AGYEJ
AIEXJ
AIKHN
AITUG
AJOXV
AJRQY
AJUYK
AKRWK
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ANZVX
AXJTR
BKOJK
BLXMC
BNPGV
EBS
EFJIC
EJD
EP2
EP3
F5P
FDB
FEDTE
FIRID
FNPLU
FYGXN
GBLVA
HVGLF
HZ~
J1W
KOM
M41
MO0
MOBAO
N9A
O-L
O9-
OAUVE
OH0
OKEIE
OU-
OZT
P-8
P-9
P2P
PC.
Q38
RIG
ROL
SDF
SEL
SES
SPCBC
SSB
SSH
SSN
SSY
SSZ
T5K
UNMZH
Z5R
~G-
AADPK
AAIAV
ABLVK
ABYKQ
AFYLN
AJBFU
EFLBG
LCYCR
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
ACRPL
ADNMO
CITATION
7X8
ID FETCH-LOGICAL-c408t-26860f3cdb6f5d36d1ebce1579850b1c372824ae29e8ac88c3c11e64e35d86113
IEDL.DBID AIKHN
ISSN 1876-2018
IngestDate Fri Oct 25 05:40:28 EDT 2024
Fri Dec 06 03:54:46 EST 2024
Sat Sep 28 08:51:12 EDT 2024
Fri Feb 23 02:26:29 EST 2024
Tue Oct 15 22:54:19 EDT 2024
IsPeerReviewed true
IsScholarly true
Keywords Buprenorphine
Treatment resistant depression
Language English
License Copyright © 2017 Elsevier B.V. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c408t-26860f3cdb6f5d36d1ebce1579850b1c372824ae29e8ac88c3c11e64e35d86113
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
PMID 28483102
PQID 1896894043
PQPubID 23479
PageCount 5
ParticipantIDs proquest_miscellaneous_1896894043
crossref_primary_10_1016_j_ajp_2017_01_015
pubmed_primary_28483102
elsevier_sciencedirect_doi_10_1016_j_ajp_2017_01_015
elsevier_clinicalkeyesjournals_1_s2_0_S1876201816302738
PublicationCentury 2000
PublicationDate 2017-04-01
PublicationDateYYYYMMDD 2017-04-01
PublicationDate_xml – month: 04
  year: 2017
  text: 2017-04-01
  day: 01
PublicationDecade 2010
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle Asian journal of psychiatry
PublicationTitleAlternate Asian J Psychiatr
PublicationYear 2017
Publisher Elsevier B.V
Publisher_xml – name: Elsevier B.V
References Fava, Memisoglu, Thase (bib0065) 2016; 173
Terenius, Wahlström, Agren (bib0190) 1977; 54
Carlezon, Beguin, Knoll (bib0040) 2009; 123
Cowan (bib0045) 2003; 133
Hustveit, Maurset, Oye (bib0100) 1995; 77
Kessler, Berglund, Demler (bib0115) 2005; 62
Nyhuis, Gastpar, Scherbaum (bib0145) 2008; 28
Hirschfeld, Montgomery, Aguglia (bib0095) 2002; 63
Dahan, Yassen, Romberg (bib0050) 2006; 96
Strain, Harrison, Bigelow (bib0180) 2011; 89
Mion, Villevieille (bib0135) 2013; 19
Mongan, Callaway (bib0140) 1990; 28
Bromet, Andrade, Hwang (bib0025) 2011; 9
Gabilondo, Meana, Garcia-Sevilla (bib0075) 1995; 682
Karp, Butler, Begley (bib0105) 2014; 75
Scarone, Gambini, Calabrese (bib0170) 1990; 32
Kennedy, Koeppe, Young (bib0110) 2006; 63
Yovell, Bar, Mashiah (bib0205) 2016; 173
Webber, Emrich (bib0200) 1988; 3
Berrocoso, Sánchez-Blázquez, Garzón (bib0015) 2009; 15
American Psychiatric Association (bib0005) 2010
Walsh, Preston, Stitzer (bib0195) 1994; 55
Kosten, Morgan, Kosten (bib0120) 1990; 7
Butler (bib0030) 2013; 4
Tenore (bib0185) 2008; 27
Emrich, Vogt, Herz (bib0060) 1982; 398
Gross-Isseroff, Dillon, Israeli (bib0090) 1990; 530
Resnick, Falk (bib0155) 1987
Callaway (bib0035) 1996; 39
Stotts, Dodrill, Kosten (bib0175) 2009; 10
Zarate, Duman, Liu (bib0210) 2013; 1292
Lofwall, Walsh (bib0130) 2014; 8
Bodkin, Zornberg, Lukas (bib0020) 1995; 15
Leander (bib0125) 1987; 26
Prudic, Haskett, Mulsant (bib0150) 1996; 153
Gaynes, Warden, Trivedi (bib0080) 2009; 60
Gerra, Fantoma, Zaimovic (bib0085) 2006; 20
Rosenthal, Ling, Casadonte (bib0160) 2013; 108
Substance Abuse and Mental Health Services Administration (SAMHSA) (bib0165) 2014
Ferrari, Charlson, Norman (bib0070) 2013; 10
Bals-Kubik, Ableitner, Herz (bib0010) 1993; 264
Ehrich, Turncliff, Du (bib0055) 2015; 40
Gerra (10.1016/j.ajp.2017.01.015_bib0085) 2006; 20
Hustveit (10.1016/j.ajp.2017.01.015_bib0100) 1995; 77
Karp (10.1016/j.ajp.2017.01.015_bib0105) 2014; 75
Bals-Kubik (10.1016/j.ajp.2017.01.015_bib0010) 1993; 264
Lofwall (10.1016/j.ajp.2017.01.015_bib0130) 2014; 8
Callaway (10.1016/j.ajp.2017.01.015_bib0035) 1996; 39
Hirschfeld (10.1016/j.ajp.2017.01.015_bib0095) 2002; 63
Nyhuis (10.1016/j.ajp.2017.01.015_bib0145) 2008; 28
Gross-Isseroff (10.1016/j.ajp.2017.01.015_bib0090) 1990; 530
Stotts (10.1016/j.ajp.2017.01.015_bib0175) 2009; 10
Bodkin (10.1016/j.ajp.2017.01.015_bib0020) 1995; 15
Dahan (10.1016/j.ajp.2017.01.015_bib0050) 2006; 96
Scarone (10.1016/j.ajp.2017.01.015_bib0170) 1990; 32
Emrich (10.1016/j.ajp.2017.01.015_bib0060) 1982; 398
Substance Abuse and Mental Health Services Administration (SAMHSA) (10.1016/j.ajp.2017.01.015_bib0165) 2014
Butler (10.1016/j.ajp.2017.01.015_bib0030) 2013; 4
Kosten (10.1016/j.ajp.2017.01.015_bib0120) 1990; 7
Gaynes (10.1016/j.ajp.2017.01.015_bib0080) 2009; 60
Resnick (10.1016/j.ajp.2017.01.015_bib0155) 1987
Walsh (10.1016/j.ajp.2017.01.015_bib0195) 1994; 55
Rosenthal (10.1016/j.ajp.2017.01.015_bib0160) 2013; 108
Leander (10.1016/j.ajp.2017.01.015_bib0125) 1987; 26
Fava (10.1016/j.ajp.2017.01.015_bib0065) 2016; 173
Bromet (10.1016/j.ajp.2017.01.015_bib0025) 2011; 9
Ferrari (10.1016/j.ajp.2017.01.015_bib0070) 2013; 10
Ehrich (10.1016/j.ajp.2017.01.015_bib0055) 2015; 40
Webber (10.1016/j.ajp.2017.01.015_bib0200) 1988; 3
Prudic (10.1016/j.ajp.2017.01.015_bib0150) 1996; 153
Berrocoso (10.1016/j.ajp.2017.01.015_bib0015) 2009; 15
Kessler (10.1016/j.ajp.2017.01.015_bib0115) 2005; 62
Tenore (10.1016/j.ajp.2017.01.015_bib0185) 2008; 27
Cowan (10.1016/j.ajp.2017.01.015_bib0045) 2003; 133
Kennedy (10.1016/j.ajp.2017.01.015_bib0110) 2006; 63
Strain (10.1016/j.ajp.2017.01.015_bib0180) 2011; 89
Yovell (10.1016/j.ajp.2017.01.015_bib0205) 2016; 173
Zarate (10.1016/j.ajp.2017.01.015_bib0210) 2013; 1292
Mion (10.1016/j.ajp.2017.01.015_bib0135) 2013; 19
American Psychiatric Association (10.1016/j.ajp.2017.01.015_bib0005) 2010
Carlezon (10.1016/j.ajp.2017.01.015_bib0040) 2009; 123
Gabilondo (10.1016/j.ajp.2017.01.015_bib0075) 1995; 682
Mongan (10.1016/j.ajp.2017.01.015_bib0140) 1990; 28
Terenius (10.1016/j.ajp.2017.01.015_bib0190) 1977; 54
References_xml – volume: 15
  start-page: 49
  year: 1995
  end-page: 57
  ident: bib0020
  article-title: Buprenorphine treatment of refractory depression
  publication-title: J. Clin. Psychopharmacol.
  contributor:
    fullname: Lukas
– volume: 173
  start-page: 5 499
  year: 2016
  end-page: 508
  ident: bib0065
  article-title: Opioid Modulation with Buprenorphine/Samidorphan as adjunctive treatment for inadequate response to antidepressants: a randomized double-blind placebo-controlled trial
  publication-title: The Am. J. Psychiatry
  contributor:
    fullname: Thase
– volume: 75
  start-page: e785
  year: 2014
  end-page: e793
  ident: bib0105
  article-title: Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults
  publication-title: J. Clin. Psychiatry
  contributor:
    fullname: Begley
– volume: 32
  start-page: 159
  year: 1990
  end-page: 166
  ident: bib0170
  article-title: Asymmetrical distribution of beta-endorphin in cerebral hemispheres of suicides: preliminary data
  publication-title: Psychiatry Res.
  contributor:
    fullname: Calabrese
– volume: 60
  start-page: 1439
  year: 2009
  end-page: 1445
  ident: bib0080
  article-title: What did STAR* teach us? Results from a large-scale, practical, clinical trial for patients with depression
  publication-title: Psychiatr. Serv.
  contributor:
    fullname: Trivedi
– volume: 4
  start-page: 148
  year: 2013
  end-page: 152
  ident: bib0030
  article-title: Buprenorphine clinically useful but often misunderstood
  publication-title: Scand. J. Pain
  contributor:
    fullname: Butler
– volume: 20
  start-page: 806
  year: 2006
  end-page: 814
  ident: bib0085
  article-title: Naltrexone and buprenorphine combination in the treatment of opioid dependence
  publication-title: J. Psychopharmacol.
  contributor:
    fullname: Zaimovic
– volume: 40
  start-page: 1448
  year: 2015
  end-page: 1455
  ident: bib0055
  article-title: Evaluation of opioid modulation n major depressive disorder
  publication-title: Neuropsychopharmacology
  contributor:
    fullname: Du
– volume: 63
  start-page: 1199
  year: 2006
  end-page: 1208
  ident: bib0110
  article-title: Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women
  publication-title: Arch. Gen. Psychiatry
  contributor:
    fullname: Young
– year: 2014
  ident: bib0165
  article-title: Buprenorphine summit
  publication-title: Report of Proceedings
  contributor:
    fullname: Substance Abuse and Mental Health Services Administration (SAMHSA)
– volume: 1292
  start-page: 21
  year: 2013
  end-page: 31
  ident: bib0210
  article-title: New paradigms for treatment resistant depression
  publication-title: Ann. N. Y. Acad. Sci.
  contributor:
    fullname: Liu
– volume: 96
  start-page: 627
  year: 2006
  end-page: 632
  ident: bib0050
  article-title: Buprenorphine induces ceiling in respiratory depression but not in analgesia
  publication-title: Br. J. Anaesth.
  contributor:
    fullname: Romberg
– volume: 89
  start-page: 443
  year: 2011
  end-page: 449
  ident: bib0180
  article-title: Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble films
  publication-title: Clin. Pharmacol. Ther.
  contributor:
    fullname: Bigelow
– volume: 7
  start-page: 51
  year: 1990
  end-page: 54
  ident: bib0120
  article-title: Depressive symptoms during buprenorphine treatment of opioid abusers
  publication-title: J. Subst. Abuse Treat.
  contributor:
    fullname: Kosten
– start-page: 280
  year: 1987
  ident: bib0155
  article-title: Buprenorphine: pilot trials in borderline patients and opiate dependence – treatment of a common disorder?
  publication-title: Problems of Drug Dependence. NIDA Research Monograph
  contributor:
    fullname: Falk
– volume: 55
  start-page: 569
  year: 1994
  end-page: 580
  ident: bib0195
  article-title: Clinical pharmacology of buprenorphine: ceiling effects at high doses
  publication-title: Clin. Pharmacol. Ther.
  contributor:
    fullname: Stitzer
– volume: 3
  start-page: 255
  year: 1988
  end-page: 266
  ident: bib0200
  article-title: Current and historical concepts of opiate treatment in psychiatric disorders
  publication-title: Int. Clin. Psychopharmacol.
  contributor:
    fullname: Emrich
– year: 2010
  ident: bib0005
  article-title: Practice Guideline for the Treatment of Patients with Major Depressive Disorder
  contributor:
    fullname: American Psychiatric Association
– volume: 153
  start-page: 985
  year: 1996
  end-page: 992
  ident: bib0150
  article-title: Resistance to antidepressant medications and short-term clinical response to ECT
  publication-title: Am. J. Psychiatry
  contributor:
    fullname: Mulsant
– volume: 173
  start-page: 491
  year: 2016
  end-page: 498
  ident: bib0205
  article-title: Ultra-Low dose buprenorphine as a time limited treatment for severe suicidal ideation: a randomized controlled trial
  publication-title: Am. J. Psychiatry
  contributor:
    fullname: Mashiah
– volume: 39
  start-page: 989
  year: 1996
  end-page: 990
  ident: bib0035
  article-title: Buprenorphine for depression: the un-adoptable orphan
  publication-title: Biol. Psychiatry
  contributor:
    fullname: Callaway
– volume: 19
  start-page: 370
  year: 2013
  end-page: 380
  ident: bib0135
  article-title: Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings)
  publication-title: CNS Neurosci. Ther.
  contributor:
    fullname: Villevieille
– volume: 530
  start-page: 312
  year: 1990
  end-page: 316
  ident: bib0090
  article-title: Regionally selective increases in mu opioid receptor density in the brains of suicide victims
  publication-title: Brain Res.
  contributor:
    fullname: Israeli
– volume: 10
  start-page: e1001547
  year: 2013
  ident: bib0070
  article-title: Burden of depressive disorders by country, sex age, and year: findings from the global burden of disease study 2010
  publication-title: PLoS Med.
  contributor:
    fullname: Norman
– volume: 8
  start-page: 315
  year: 2014
  end-page: 326
  ident: bib0130
  article-title: A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world
  publication-title: J. Addict. Med.
  contributor:
    fullname: Walsh
– volume: 682
  start-page: 245
  year: 1995
  end-page: 250
  ident: bib0075
  article-title: Increased density of μ-opioid receptors in the postmortem brain of suicide victims
  publication-title: Brain Res.
  contributor:
    fullname: Garcia-Sevilla
– volume: 264
  start-page: 489
  year: 1993
  end-page: 495
  ident: bib0010
  article-title: Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats
  publication-title: J. Pharmacol. Exp. Ther.
  contributor:
    fullname: Herz
– volume: 28
  start-page: 1078
  year: 1990
  end-page: 1080
  ident: bib0140
  article-title: Buprenorphine responders
  publication-title: Biol. Psychiatry
  contributor:
    fullname: Callaway
– volume: 27
  start-page: 49
  year: 2008
  end-page: 65
  ident: bib0185
  article-title: Psychotherapeutic benefits of opioid agonist therapy
  publication-title: J. Addict. Dis.
  contributor:
    fullname: Tenore
– volume: 77
  start-page: 355
  year: 1995
  end-page: 359
  ident: bib0100
  article-title: Interaction of the chiral forms of ketamine with opioid, phencyclidine, and muscarinic receptors
  publication-title: Pharmacol. Toxicol.
  contributor:
    fullname: Oye
– volume: 54
  start-page: 31
  year: 1977
  end-page: 33
  ident: bib0190
  article-title: Naloxone (Narcan) treatment in depression: clinical observations and effects on CSF endorphins and monoamine metabolites
  publication-title: Psychopharmacology (Berl)
  contributor:
    fullname: Agren
– volume: 15
  start-page: 1612
  year: 2009
  end-page: 1622
  ident: bib0015
  article-title: Opiates as antidepressants
  publication-title: Curr. Pharm. Des.
  contributor:
    fullname: Garzón
– volume: 10
  start-page: 1727
  year: 2009
  end-page: 1740
  ident: bib0175
  article-title: Opioid dependence treatment: options in pharmacotherapy
  publication-title: Expert Opin. Pharmacother.
  contributor:
    fullname: Kosten
– volume: 63
  start-page: 826
  year: 2002
  end-page: 837
  ident: bib0095
  article-title: Partial response and nonresponse to antidepressant therapy: current approaches and treatment options
  publication-title: J. Clin. Psychiatry
  contributor:
    fullname: Aguglia
– volume: 26
  start-page: 1445
  year: 1987
  end-page: 1447
  ident: bib0125
  article-title: Buprenorphine has potent kappa opioid receptor antagonist activity
  publication-title: Neuropharmacology
  contributor:
    fullname: Leander
– volume: 123
  start-page: 334
  year: 2009
  end-page: 343
  ident: bib0040
  article-title: Kappa-opioid ligands in the study and treatment of mood disorders
  publication-title: Pharmacol. Ther.
  contributor:
    fullname: Knoll
– volume: 108
  start-page: 2141
  year: 2013
  end-page: 2149
  ident: bib0160
  article-title: Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone
  publication-title: Addiction
  contributor:
    fullname: Casadonte
– volume: 398
  start-page: 108
  year: 1982
  end-page: 112
  ident: bib0060
  article-title: Possible antidepressive effects of opioids: action of buprenorphine
  publication-title: Ann. N. Y. Acad. Sci.
  contributor:
    fullname: Herz
– volume: 9
  start-page: 90
  year: 2011
  ident: bib0025
  article-title: Cross-national epidemiology of DSM-IV major depressive episode
  publication-title: BMC Med.
  contributor:
    fullname: Hwang
– volume: 133
  start-page: 3
  year: 2003
  end-page: 8
  ident: bib0045
  article-title: Buprenorphine new pharmacological aspects
  publication-title: Int. J. Clin. Pract. Suppl.
  contributor:
    fullname: Cowan
– volume: 62
  start-page: 593
  year: 2005
  end-page: 602
  ident: bib0115
  article-title: Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication
  publication-title: Arch. Gen. Psychiatry
  contributor:
    fullname: Demler
– volume: 28
  start-page: 593
  year: 2008
  end-page: 595
  ident: bib0145
  article-title: Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy
  publication-title: J. Clin. Psychopharmacol.
  contributor:
    fullname: Scherbaum
– volume: 123
  start-page: 334
  year: 2009
  ident: 10.1016/j.ajp.2017.01.015_bib0040
  article-title: Kappa-opioid ligands in the study and treatment of mood disorders
  publication-title: Pharmacol. Ther.
  doi: 10.1016/j.pharmthera.2009.05.008
  contributor:
    fullname: Carlezon
– volume: 40
  start-page: 1448
  year: 2015
  ident: 10.1016/j.ajp.2017.01.015_bib0055
  article-title: Evaluation of opioid modulation n major depressive disorder
  publication-title: Neuropsychopharmacology
  doi: 10.1038/npp.2014.330
  contributor:
    fullname: Ehrich
– volume: 133
  start-page: 3
  year: 2003
  ident: 10.1016/j.ajp.2017.01.015_bib0045
  article-title: Buprenorphine new pharmacological aspects
  publication-title: Int. J. Clin. Pract. Suppl.
  contributor:
    fullname: Cowan
– volume: 62
  start-page: 593
  issue: 6
  year: 2005
  ident: 10.1016/j.ajp.2017.01.015_bib0115
  article-title: Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication
  publication-title: Arch. Gen. Psychiatry
  doi: 10.1001/archpsyc.62.6.593
  contributor:
    fullname: Kessler
– volume: 32
  start-page: 159
  year: 1990
  ident: 10.1016/j.ajp.2017.01.015_bib0170
  article-title: Asymmetrical distribution of beta-endorphin in cerebral hemispheres of suicides: preliminary data
  publication-title: Psychiatry Res.
  doi: 10.1016/0165-1781(90)90082-G
  contributor:
    fullname: Scarone
– volume: 15
  start-page: 1612
  year: 2009
  ident: 10.1016/j.ajp.2017.01.015_bib0015
  article-title: Opiates as antidepressants
  publication-title: Curr. Pharm. Des.
  doi: 10.2174/138161209788168100
  contributor:
    fullname: Berrocoso
– volume: 54
  start-page: 31
  issue: 1
  year: 1977
  ident: 10.1016/j.ajp.2017.01.015_bib0190
  article-title: Naloxone (Narcan) treatment in depression: clinical observations and effects on CSF endorphins and monoamine metabolites
  publication-title: Psychopharmacology (Berl)
  doi: 10.1007/BF00426537
  contributor:
    fullname: Terenius
– volume: 173
  start-page: 5 499
  year: 2016
  ident: 10.1016/j.ajp.2017.01.015_bib0065
  article-title: Opioid Modulation with Buprenorphine/Samidorphan as adjunctive treatment for inadequate response to antidepressants: a randomized double-blind placebo-controlled trial
  publication-title: The Am. J. Psychiatry
  doi: 10.1176/appi.ajp.2015.15070921
  contributor:
    fullname: Fava
– volume: 75
  start-page: e785
  year: 2014
  ident: 10.1016/j.ajp.2017.01.015_bib0105
  article-title: Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults
  publication-title: J. Clin. Psychiatry
  doi: 10.4088/JCP.13m08725
  contributor:
    fullname: Karp
– start-page: 280
  year: 1987
  ident: 10.1016/j.ajp.2017.01.015_bib0155
  article-title: Buprenorphine: pilot trials in borderline patients and opiate dependence – treatment of a common disorder?
  contributor:
    fullname: Resnick
– volume: 39
  start-page: 989
  year: 1996
  ident: 10.1016/j.ajp.2017.01.015_bib0035
  article-title: Buprenorphine for depression: the un-adoptable orphan
  publication-title: Biol. Psychiatry
  doi: 10.1016/0006-3223(96)00158-8
  contributor:
    fullname: Callaway
– volume: 77
  start-page: 355
  year: 1995
  ident: 10.1016/j.ajp.2017.01.015_bib0100
  article-title: Interaction of the chiral forms of ketamine with opioid, phencyclidine, and muscarinic receptors
  publication-title: Pharmacol. Toxicol.
  doi: 10.1111/j.1600-0773.1995.tb01041.x
  contributor:
    fullname: Hustveit
– volume: 9
  start-page: 90
  year: 2011
  ident: 10.1016/j.ajp.2017.01.015_bib0025
  article-title: Cross-national epidemiology of DSM-IV major depressive episode
  publication-title: BMC Med.
  doi: 10.1186/1741-7015-9-90
  contributor:
    fullname: Bromet
– volume: 530
  start-page: 312
  year: 1990
  ident: 10.1016/j.ajp.2017.01.015_bib0090
  article-title: Regionally selective increases in mu opioid receptor density in the brains of suicide victims
  publication-title: Brain Res.
  doi: 10.1016/0006-8993(90)91301-V
  contributor:
    fullname: Gross-Isseroff
– volume: 10
  start-page: 1727
  year: 2009
  ident: 10.1016/j.ajp.2017.01.015_bib0175
  article-title: Opioid dependence treatment: options in pharmacotherapy
  publication-title: Expert Opin. Pharmacother.
  doi: 10.1517/14656560903037168
  contributor:
    fullname: Stotts
– volume: 10
  start-page: e1001547
  issue: 11
  year: 2013
  ident: 10.1016/j.ajp.2017.01.015_bib0070
  article-title: Burden of depressive disorders by country, sex age, and year: findings from the global burden of disease study 2010
  publication-title: PLoS Med.
  doi: 10.1371/journal.pmed.1001547
  contributor:
    fullname: Ferrari
– volume: 60
  start-page: 1439
  issue: 11
  year: 2009
  ident: 10.1016/j.ajp.2017.01.015_bib0080
  article-title: What did STAR* teach us? Results from a large-scale, practical, clinical trial for patients with depression
  publication-title: Psychiatr. Serv.
  doi: 10.1176/ps.2009.60.11.1439
  contributor:
    fullname: Gaynes
– volume: 28
  start-page: 593
  year: 2008
  ident: 10.1016/j.ajp.2017.01.015_bib0145
  article-title: Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy
  publication-title: J. Clin. Psychopharmacol.
  doi: 10.1097/JCP.0b013e31818638a4
  contributor:
    fullname: Nyhuis
– volume: 89
  start-page: 443
  year: 2011
  ident: 10.1016/j.ajp.2017.01.015_bib0180
  article-title: Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble films
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1038/clpt.2010.352
  contributor:
    fullname: Strain
– volume: 19
  start-page: 370
  issue: 6
  year: 2013
  ident: 10.1016/j.ajp.2017.01.015_bib0135
  article-title: Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings)
  publication-title: CNS Neurosci. Ther.
  doi: 10.1111/cns.12099
  contributor:
    fullname: Mion
– volume: 398
  start-page: 108
  year: 1982
  ident: 10.1016/j.ajp.2017.01.015_bib0060
  article-title: Possible antidepressive effects of opioids: action of buprenorphine
  publication-title: Ann. N. Y. Acad. Sci.
  doi: 10.1111/j.1749-6632.1982.tb39483.x
  contributor:
    fullname: Emrich
– volume: 27
  start-page: 49
  year: 2008
  ident: 10.1016/j.ajp.2017.01.015_bib0185
  article-title: Psychotherapeutic benefits of opioid agonist therapy
  publication-title: J. Addict. Dis.
  doi: 10.1080/10550880802122646
  contributor:
    fullname: Tenore
– volume: 20
  start-page: 806
  year: 2006
  ident: 10.1016/j.ajp.2017.01.015_bib0085
  article-title: Naltrexone and buprenorphine combination in the treatment of opioid dependence
  publication-title: J. Psychopharmacol.
  doi: 10.1177/0269881106060835
  contributor:
    fullname: Gerra
– volume: 15
  start-page: 49
  year: 1995
  ident: 10.1016/j.ajp.2017.01.015_bib0020
  article-title: Buprenorphine treatment of refractory depression
  publication-title: J. Clin. Psychopharmacol.
  doi: 10.1097/00004714-199502000-00008
  contributor:
    fullname: Bodkin
– volume: 55
  start-page: 569
  issue: 5
  year: 1994
  ident: 10.1016/j.ajp.2017.01.015_bib0195
  article-title: Clinical pharmacology of buprenorphine: ceiling effects at high doses
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1038/clpt.1994.71
  contributor:
    fullname: Walsh
– volume: 108
  start-page: 2141
  year: 2013
  ident: 10.1016/j.ajp.2017.01.015_bib0160
  article-title: Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone
  publication-title: Addiction
  doi: 10.1111/add.12315
  contributor:
    fullname: Rosenthal
– volume: 3
  start-page: 255
  issue: 3
  year: 1988
  ident: 10.1016/j.ajp.2017.01.015_bib0200
  article-title: Current and historical concepts of opiate treatment in psychiatric disorders
  publication-title: Int. Clin. Psychopharmacol.
  doi: 10.1097/00004850-198807000-00007
  contributor:
    fullname: Webber
– volume: 173
  start-page: 491
  issue: 5
  year: 2016
  ident: 10.1016/j.ajp.2017.01.015_bib0205
  article-title: Ultra-Low dose buprenorphine as a time limited treatment for severe suicidal ideation: a randomized controlled trial
  publication-title: Am. J. Psychiatry
  doi: 10.1176/appi.ajp.2015.15040535
  contributor:
    fullname: Yovell
– volume: 682
  start-page: 245
  year: 1995
  ident: 10.1016/j.ajp.2017.01.015_bib0075
  article-title: Increased density of μ-opioid receptors in the postmortem brain of suicide victims
  publication-title: Brain Res.
  doi: 10.1016/0006-8993(95)00333-L
  contributor:
    fullname: Gabilondo
– year: 2014
  ident: 10.1016/j.ajp.2017.01.015_bib0165
  article-title: Buprenorphine summit
  contributor:
    fullname: Substance Abuse and Mental Health Services Administration (SAMHSA)
– volume: 153
  start-page: 985
  year: 1996
  ident: 10.1016/j.ajp.2017.01.015_bib0150
  article-title: Resistance to antidepressant medications and short-term clinical response to ECT
  publication-title: Am. J. Psychiatry
  doi: 10.1176/ajp.153.8.985
  contributor:
    fullname: Prudic
– volume: 264
  start-page: 489
  year: 1993
  ident: 10.1016/j.ajp.2017.01.015_bib0010
  article-title: Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats
  publication-title: J. Pharmacol. Exp. Ther.
  contributor:
    fullname: Bals-Kubik
– year: 2010
  ident: 10.1016/j.ajp.2017.01.015_bib0005
  contributor:
    fullname: American Psychiatric Association
– volume: 7
  start-page: 51
  year: 1990
  ident: 10.1016/j.ajp.2017.01.015_bib0120
  article-title: Depressive symptoms during buprenorphine treatment of opioid abusers
  publication-title: J. Subst. Abuse Treat.
  doi: 10.1016/0740-5472(90)90035-O
  contributor:
    fullname: Kosten
– volume: 1292
  start-page: 21
  year: 2013
  ident: 10.1016/j.ajp.2017.01.015_bib0210
  article-title: New paradigms for treatment resistant depression
  publication-title: Ann. N. Y. Acad. Sci.
  doi: 10.1111/nyas.12223
  contributor:
    fullname: Zarate
– volume: 4
  start-page: 148
  year: 2013
  ident: 10.1016/j.ajp.2017.01.015_bib0030
  article-title: Buprenorphine clinically useful but often misunderstood
  publication-title: Scand. J. Pain
  doi: 10.1016/j.sjpain.2013.05.004
  contributor:
    fullname: Butler
– volume: 96
  start-page: 627
  year: 2006
  ident: 10.1016/j.ajp.2017.01.015_bib0050
  article-title: Buprenorphine induces ceiling in respiratory depression but not in analgesia
  publication-title: Br. J. Anaesth.
  doi: 10.1093/bja/ael051
  contributor:
    fullname: Dahan
– volume: 63
  start-page: 1199
  year: 2006
  ident: 10.1016/j.ajp.2017.01.015_bib0110
  article-title: Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women
  publication-title: Arch. Gen. Psychiatry
  doi: 10.1001/archpsyc.63.11.1199
  contributor:
    fullname: Kennedy
– volume: 8
  start-page: 315
  year: 2014
  ident: 10.1016/j.ajp.2017.01.015_bib0130
  article-title: A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world
  publication-title: J. Addict. Med.
  doi: 10.1097/ADM.0000000000000045
  contributor:
    fullname: Lofwall
– volume: 28
  start-page: 1078
  year: 1990
  ident: 10.1016/j.ajp.2017.01.015_bib0140
  article-title: Buprenorphine responders
  publication-title: Biol. Psychiatry
  doi: 10.1016/0006-3223(90)90619-D
  contributor:
    fullname: Mongan
– volume: 26
  start-page: 1445
  year: 1987
  ident: 10.1016/j.ajp.2017.01.015_bib0125
  article-title: Buprenorphine has potent kappa opioid receptor antagonist activity
  publication-title: Neuropharmacology
  doi: 10.1016/0028-3908(87)90112-2
  contributor:
    fullname: Leander
– volume: 63
  start-page: 826
  year: 2002
  ident: 10.1016/j.ajp.2017.01.015_bib0095
  article-title: Partial response and nonresponse to antidepressant therapy: current approaches and treatment options
  publication-title: J. Clin. Psychiatry
  doi: 10.4088/JCP.v63n0913
  contributor:
    fullname: Hirschfeld
SSID ssj0068347
Score 2.2221975
SecondaryResourceType review_article
Snippet Highlights • For treatment resistant depression, augmentation strategies may improve outcome in some, leaving many with disabling and distressing residual...
•For treatment resistant depression, augmentation strategies may improve outcome in some, leaving many with disabling and distressing residual symptoms.•Based...
Current treatment strategies for depressive disorders have limited efficacy, leaving many patients unimproved or with significant residual symptoms. The...
OBJECTIVECurrent treatment strategies for depressive disorders have limited efficacy, leaving many patients unimproved or with significant residual symptoms....
SourceID proquest
crossref
pubmed
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 94
SubjectTerms Analgesics, Opioid - therapeutic use
Antidepressive Agents - therapeutic use
Buprenorphine
Buprenorphine - therapeutic use
Depressive Disorder, Treatment-Resistant - drug therapy
Humans
Internal Medicine
Psychiatry
Treatment Outcome
Treatment resistant depression
Title Use of Buprenorphine in treatment of refractory depression—A review of current literature
URI https://www.clinicalkey.es/playcontent/1-s2.0-S1876201816302738
https://dx.doi.org/10.1016/j.ajp.2017.01.015
https://www.ncbi.nlm.nih.gov/pubmed/28483102
https://search.proquest.com/docview/1896894043
Volume 26
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB7ygNJLSd-bFyr0VHDXesvHTUjYpCSXdiHQg7BsGTYUb8juHnoJ-RH5hfklmfELSh-Hgi-WJSRGmoc8M98AfAzKahHKKnGlFImqVEhyK1RSEha5C1mlKvrfcXFppjN1fqWvNuC4z4WhsMpO9rcyvZHWXcu4o-b4Zj4ff-XEyIQ3ZWQDyrIJ26iOyFe7PTn7Mr3sBbJxsqkzRv0TGtA7N5swr_yaUCu5bcA7qTjun9XT38zPRg2d7sCLzn5kk3aJL2Ej1q_g2UXnIX8N32fLyBYVO1oTWOUCqYjNbF6zIaKcvuK8t02hnZ9sCIWtH-8fJqxNZaE-RYvcxH4MwMtvYHZ68u14mnQFFJJCpW6VCONMWsmCUu10KU3JYygi1zZzOg28kBYvXCqPIosuL5wrZMF5NCpKXTrDuXwLW_Wiju-BWWR2Y7Is2FyrIEXuosDLEAoIqy2acCP41NPN37Q4Gb4PILv2SGRPRPYpx0ePwPaU9X0CKIqsuOz4Z-m5Xwqf-t_2eARqGPnLMfGoAf414Yd-_zyyD_lE8jou1jiRy4zLCGJoBO_ajR3Wj5qbyrCJ3f-bdA-e01sb5rMPW6vbdTxAC2YVDmHz8x0_7M7pE-O-7kQ
link.rule.ids 314,780,784,4502,24116,27924,27925,45585,45679
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB7SBNpeQtPnJm2qQk8Fd623fExCwibN5tIsBHoQli3DhuIN2d1DL6U_or-wv6QzfkHo4xDwSZI9YqQZSdY33wC8D8pqEcoqcaUUiapUSHIrVFISF7kLWaUq-t8xvTCTmTq70lcbcNTHwhCssvP9rU9vvHVXMu60Ob6Zz8efORky8U0Z2ZCyPIAthd8nXN_H7wPOwzjZZBmj1gk17682G5BXfk2cldw21J2UGvfvi9O_Np_NInTyBLa73SM7aDu4AxuxfgoPp939-DP4MltGtqjY4ZqoKheoQyxm85oNeHKqRbm3TZqdb2wAwta_fvw8YG0gC7UpWt4m9nWgXX4Os5Pjy6NJ0qVPSAqVulUijDNpJQsKtNOlNCWPoYhc28zpNPBCWjxuqTyKLLq8cK6QBefRqCh16Qzn8gVs1os6vgJm0dSNybJgc62CFLmLAo9C6B6striBG8GHXm_-pmXJ8D187Nqjkj0p2accHz0C22vW9-Gf6LDisrOeped-KXzq_xjhEajhzTuTxKP__5_Ad_34eTQeuhHJ67hYoyCXGZcRwdAIXrYDO_Qf121KwiZ27yf0LTyaXE7P_fnpxac9eEw1LeDnNWyubtfxDe5lVmG_mau_AQnH7x0
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Use+of+Buprenorphine+in+treatment+of+refractory+depression%E2%80%94A+review+of+current+literature&rft.jtitle=Asian+journal+of+psychiatry&rft.au=Stanciu%2C+Cornel+N.&rft.au=Glass%2C+Oliver+M.&rft.au=Penders%2C+Thomas+M.&rft.date=2017-04-01&rft.pub=Elsevier+B.V&rft.issn=1876-2018&rft.eissn=1876-2026&rft.volume=26&rft.spage=94&rft.epage=98&rft_id=info:doi/10.1016%2Fj.ajp.2017.01.015&rft.externalDocID=S1876201816302738
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F18762018%2Fcov200h.gif